Recent breakthroughs in radionuclide breast cancer imaging are transforming how clinicians approach patient stratification and treatment monitoring. While traditional [18F]FDG PET/CT remains a cornerstone for staging, its sensitivity for small lesions and specificity can sometimes be insufficient. Furthermore, assessing bone-predominant disease and inter-lesional heterogeneity poses significant challenges for standard RECIST or PERCIST criteria. Consequently, researchers are shifting focus toward more specific molecular targets. Moreover, these advanced tools enable a more comprehensive assessment of the disease state than traditional methods.

Benefits of Advanced Radionuclide Breast Cancer Imaging

Specifically, recent studies emphasize that receptor-mediated nuclear imaging provides non-invasive, whole-body phenotyping. Therefore, this approach maps spatial heterogeneity more accurately than a single site biopsy. Significant clinical progress has occurred with tracers targeting steroid receptors like ER, PR, and AR, as well as HER2. Additionally, fibroblast activation protein (FAP) imaging via FAPI tracers is emerging as a powerful tool for oncology. Similarly, visualizing the tumor microenvironment helps clinicians tailor treatment plans effectively because it identifies the underlying biology of all lesions.

Emerging Targets and Theranostic Potential

Furthermore, novel targets such as CXCR4, NTSR1, NPY1R, and TROP-2 are broadening the theranostic landscape. These tracers are particularly valuable when biomarker profiles evolve over time. Consequently, multi-target imaging strategies allow physicians to better address the complexity of intra-lesional heterogeneity. However, larger prospective cohorts remain necessary to define the definitive diagnostic performance. Thus, molecular imaging continues to bridge the gap between diagnosis and targeted therapy. In addition to staging, these tools provide a roadmap for personalized medicine.

Frequently Asked Questions

What are the main limitations of [18F]FDG PET/CT in breast cancer?

It often shows poor specificity and reduced sensitivity for small lesions or specific subtypes like lobular carcinoma, especially in bone-dominant disease or heterogeneous cases.

Why is FAPI imaging considered a significant advancement?

FAPI tracers target the tumor stroma rather than just the cancer cells. As a result, they offer high sensitivity for detecting both primary tumors and metastases with low background noise.

What role does whole-body phenotyping play in management?

It allows for the non-invasive mapping of spatial heterogeneity across all metastatic sites. Because it covers the entire body, it provides a more comprehensive biological profile than a localized tissue biopsy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Paraïso P et al. Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art. EJNMMI Radiopharm Chem. 2026 Apr 26. doi: 10.1186/s41181-026-00446-y. PMID: 42035386.

Hao Z, et al. FAPI versus 18F-FDG PET/CT for systemic staging of newly diagnosed breast cancer. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 2024.

Pabst K, et al. Identification of FAP-expressing tumors with Ga-68-FAPi-46 PET-CT. The Lancet Oncology. 2025.